Tangent90 Appoints Gemma Cholerton As Marketing Director

London, United Kingdom – 3rd August 2021: Tangent90 Ltd, a leading technology company developing innovative solutions that enable pharma to overcome the challenges of sharing scientific digital content with healthcare professionals (HCPs), welcome the appointment of Gemma Cholerton as Marketing Director. 

Gemma joins from global pharmaceutical regulatory solutions provider, PharmaLex, where she held a senior marketing role, leading the marketing strategy for online and digital, brand implementation and PR. In moving to Tangent90, Gemma saw an opportunity to help the company formalise its marketing activities and support its ambitious growth plans.  

“It is an exciting opportunity to join a company that is seeing significant growth, despite the challenges of the last 18 months”, explained Gemma. “Tangent90 are ahead of the curve when it comes to digital engagement through copyright scientific content and with the momentum shifting in pharma to drive the adoption of digital solutions, there’s a real opportunity to showcase what we can do”, she added. 

“As a growing company, we recognised the need to add structure to our marketing efforts”, explained Jan van den Burg, CEO at Tangent90. “Gemma’s experience is a clear advantage and will enable us to optimise the opportunity to support pharma in taking their digital communications to the next level”, he added.  

>> Download Full Article

Related news

First party data

The first-party data opportunity

The pharma industry has embraced the digital revolution and with that the opportunity to use more readily available data. However, effective digital engagement only works if first-party data (information a company collects directly from its customers and owns) is collected and subsequently used properly.

HCP access

Taking advantage of the HCP access rebound

The latest Veeva Pulse Field Trends Report is out and it discusses the change in access to HCPs. Even pre-pandemic, face-to-face meetings were in decline but the report highlights that this has bounced back, and some. The figure now sits at 60% across all specialities but what is clear is that how interaction takes place has changed.

Marketing insight

Harnessing data-driven HCP engagement

Whether it’s via email, from a congress booth, or a website, we share content with our target audience constantly. For pharma, this content can be the difference between an HCP prescribing their drug or not. It is, therefore, important to understand what happens to that content after the initial interaction with the HCP.

Scroll to Top

Book A Demo

We use cookies to improve your experience on our website. By browsing this website, you agree to our use of cookies.